Lucic Silvija, Spirovski Milena, Nikolin Borislava, Stojanovic Dragana, Peter Andrea, Gajic Branislava, Cimbaljevic Vanja, Lucic Milos A
Medical Faculty, Oncology Institute of Vojvodina, University of Novi Sad, 21000 Novi Sad, Serbia.
Oncology Institute of Vojvodina, 21000 Novi Sad, Serbia.
Diagnostics (Basel). 2025 Jun 18;15(12):1560. doi: 10.3390/diagnostics15121560.
The global increase in the incidence of malignant melanoma, without significant changes in the mortality rate, may be influenced by the changes in the diagnostic approach and criteria, and the impact of innovative therapies on the survival of patients. Advances in treatment options, influencing prolonged survival, are bringing up a strong need for close surveillance of melanoma patients. In this observational, retrospective, and single-center study, we determined the impact of 18F-FDG PET/CT diagnostics on the outcomes and survival of malignant melanoma patients at different stages from an extensive and unselected group in a real-life clinical management setting. A total number of 189 malignant melanoma patients who underwent 18F-FDG PET/CT examination in the course of the treatment at one university oncology institute during the period from January 2010 to December 2024 were included in the study, and the multifactorial impact on the outcome and survival of malignant melanoma patients was observed in regard to the differences resulting from the therapeutic approaches and the introduction of new therapeutic options and drugs. Our results indicate that 18F-FDG PET/CT is a sensitive imaging tool for the detection of predominantly distant metastases in malignant melanoma patients belonging to an extensive and unselected population in a real-world clinical setting, not only at advanced melanoma stages but also at early stages of high-risk patients' surveillance. Follow-up appears to be of substantial importance for patients at advanced stages, but also for patients at early stages of disease, in particular in the presence of a strong clinical suspicion. Immunotherapy and combined therapy are improving overall survival in melanoma patients in real-world circumstances and equivalent clinical surroundings.
全球恶性黑色素瘤发病率上升，但死亡率无显著变化，这可能受到诊断方法和标准的改变以及创新疗法对患者生存影响的影响。治疗选择的进步延长了患者生存期，这使得对黑色素瘤患者进行密切监测的需求日益强烈。在这项观察性、回顾性单中心研究中，我们在真实临床管理环境下，从一个广泛且未经过筛选的群体中，确定了18F-FDG PET/CT诊断对不同阶段恶性黑色素瘤患者的治疗结果和生存情况的影响。本研究纳入了2010年1月至2024年12月期间在一所大学肿瘤研究所接受治疗过程中进行18F-FDG PET/CT检查的189例恶性黑色素瘤患者，并观察了治疗方法以及新治疗方案和药物的引入所导致的差异对恶性黑色素瘤患者治疗结果和生存情况的多因素影响。我们的结果表明，18F-FDG PET/CT是一种敏感的成像工具，不仅在晚期黑色素瘤阶段，而且在高危患者早期监测阶段，都能在真实临床环境中检测出广泛且未经过筛选人群中恶性黑色素瘤患者的主要远处转移。随访对于晚期患者以及疾病早期患者似乎都至关重要，特别是在临床高度怀疑的情况下。在真实世界和等效临床环境中，免疫疗法和联合疗法正在改善黑色素瘤患者的总生存期。
